Prashi Jain
Director, Drug Discovery at Iterion Therapeutics- Claim this Profile
Click to upgrade to our gold package
for the full feature experience.
-
Hindi Native or bilingual proficiency
-
English Full professional proficiency
Topline Score
Bio
Conrad Santini
Prashi Jain is a highly diligent, disciplined and productive scientist. She adapts quickly to new opportunities and challenges in medicinal chemistry, high throughput synthesis and technology enhanced chemistry. As both a talented, insightful collaborator and a delightful colleague, Prashi’s professionalism will be missed when the inevitable day arrives that she leaves the University of Kansas. Whoever hires her will have made our loss their gain.
Patrick Flaherty
Dr. Jain was a graduate student from September 2005 until she successfully completed her Ph.D. in November 2011 here at Duquesne University. She is THE graduate student who got my lab up and running. She did the initial methodology development that has enabled the graduation of 2 masters students. Additionally she mentored 2 undergraduate students. The chemistry involved was heterocyclic synthesis, palladium couplings (Buchwald-Hartwig, and Molander-Suzuki), and the usual grab-bag of synthetic organic conversions. She was active in the design and synthesis of several varieties of kinase and isomerase inhibitors. Her Ph.D. work has resulted in 7 papers (as of 11/16/11) and three additional papers will be submitted. She has contributed to the writing of a NIH grant renewal and smaller grants as well. She has excellent communication skills and interacts very well with others regardless of skill level or primary scientific discipline. I highly recommend Prashi Jain and can readily confirm her professional qualifications and personal integrity. PTF 11/16/11
Conrad Santini
Prashi Jain is a highly diligent, disciplined and productive scientist. She adapts quickly to new opportunities and challenges in medicinal chemistry, high throughput synthesis and technology enhanced chemistry. As both a talented, insightful collaborator and a delightful colleague, Prashi’s professionalism will be missed when the inevitable day arrives that she leaves the University of Kansas. Whoever hires her will have made our loss their gain.
Patrick Flaherty
Dr. Jain was a graduate student from September 2005 until she successfully completed her Ph.D. in November 2011 here at Duquesne University. She is THE graduate student who got my lab up and running. She did the initial methodology development that has enabled the graduation of 2 masters students. Additionally she mentored 2 undergraduate students. The chemistry involved was heterocyclic synthesis, palladium couplings (Buchwald-Hartwig, and Molander-Suzuki), and the usual grab-bag of synthetic organic conversions. She was active in the design and synthesis of several varieties of kinase and isomerase inhibitors. Her Ph.D. work has resulted in 7 papers (as of 11/16/11) and three additional papers will be submitted. She has contributed to the writing of a NIH grant renewal and smaller grants as well. She has excellent communication skills and interacts very well with others regardless of skill level or primary scientific discipline. I highly recommend Prashi Jain and can readily confirm her professional qualifications and personal integrity. PTF 11/16/11
Conrad Santini
Prashi Jain is a highly diligent, disciplined and productive scientist. She adapts quickly to new opportunities and challenges in medicinal chemistry, high throughput synthesis and technology enhanced chemistry. As both a talented, insightful collaborator and a delightful colleague, Prashi’s professionalism will be missed when the inevitable day arrives that she leaves the University of Kansas. Whoever hires her will have made our loss their gain.
Patrick Flaherty
Dr. Jain was a graduate student from September 2005 until she successfully completed her Ph.D. in November 2011 here at Duquesne University. She is THE graduate student who got my lab up and running. She did the initial methodology development that has enabled the graduation of 2 masters students. Additionally she mentored 2 undergraduate students. The chemistry involved was heterocyclic synthesis, palladium couplings (Buchwald-Hartwig, and Molander-Suzuki), and the usual grab-bag of synthetic organic conversions. She was active in the design and synthesis of several varieties of kinase and isomerase inhibitors. Her Ph.D. work has resulted in 7 papers (as of 11/16/11) and three additional papers will be submitted. She has contributed to the writing of a NIH grant renewal and smaller grants as well. She has excellent communication skills and interacts very well with others regardless of skill level or primary scientific discipline. I highly recommend Prashi Jain and can readily confirm her professional qualifications and personal integrity. PTF 11/16/11
Conrad Santini
Prashi Jain is a highly diligent, disciplined and productive scientist. She adapts quickly to new opportunities and challenges in medicinal chemistry, high throughput synthesis and technology enhanced chemistry. As both a talented, insightful collaborator and a delightful colleague, Prashi’s professionalism will be missed when the inevitable day arrives that she leaves the University of Kansas. Whoever hires her will have made our loss their gain.
Patrick Flaherty
Dr. Jain was a graduate student from September 2005 until she successfully completed her Ph.D. in November 2011 here at Duquesne University. She is THE graduate student who got my lab up and running. She did the initial methodology development that has enabled the graduation of 2 masters students. Additionally she mentored 2 undergraduate students. The chemistry involved was heterocyclic synthesis, palladium couplings (Buchwald-Hartwig, and Molander-Suzuki), and the usual grab-bag of synthetic organic conversions. She was active in the design and synthesis of several varieties of kinase and isomerase inhibitors. Her Ph.D. work has resulted in 7 papers (as of 11/16/11) and three additional papers will be submitted. She has contributed to the writing of a NIH grant renewal and smaller grants as well. She has excellent communication skills and interacts very well with others regardless of skill level or primary scientific discipline. I highly recommend Prashi Jain and can readily confirm her professional qualifications and personal integrity. PTF 11/16/11
Credentials
-
Interpersonal Communication
LinkedInOct, 2021- Nov, 2024 -
Project Leadership
LinkedInOct, 2021- Nov, 2024 -
Influencing Others
LinkedInSep, 2021- Nov, 2024 -
Basic Immunology graduate course
Baylor College of MedicineFeb, 2021- Nov, 2024 -
Explorative Data Analysis course
Baylor College of MedicineMar, 2019- Nov, 2024 -
LIFE SCIENCE ENTREPRENEURSHIP - MGMT 633
Rice UniversityApr, 2018- Nov, 2024 -
Agilent LC/MS in-house training workshop
Agilent TechnologiesOct, 2015- Nov, 2024
Experience
-
Iterion Therapeutics
-
United States
-
Biotechnology Research
-
1 - 100 Employee
-
Director, Drug Discovery
-
Aug 2022 - Present
-
-
-
Baylor College of Medicine
-
United States
-
Higher Education
-
700 & Above Employee
-
Adjunct Professor
-
Jan 2022 - Present
-
-
Instructor
-
Oct 2018 - Jan 2022
Our work is focused on identifying the role of SRC-3, previously identified as oncogene, in Treg biology and the effect of SRC-3 modulation on cancer progression.- Identified the critical role of SRC-3 in regulatory T cells (Tregs), published in 2021.- Working with a cross-functional team to drive a cell based therapy forward against cancer.- Managed the preclinical projects and collaborated with startups to move SRC-3 inhibitor to clinic.- Expanded my skills to perform cell based in-vitro assays to find the binding site of small molecule inhibitors of SRC-3 and to understand related protein-protein interactions. Show less
-
-
Postdoctoral Fellow/ Drug discovery lead
-
Jun 2015 - Sep 2018
- Developed new methodologies for sp3 enriched disubstituted piperazine scaffolds for Fragment Based Drug Discovery (FBDD). - Led the design, development and synthesis of first-in-class 3D enriched chemical fragments.- Performed market analysis, budgeted and successfully negotiated with multiple vendors for purchasing >2500 fragments saving >$200,000 in raw material costs.- Identified needs, performed extensive market analysis and use-testing of software solutions for electronic data capture, storage, and visualization of research data in e-notebooks.- Mentored three post baccalaureate students for a year. Show less
-
-
-
Ponce Therapeutics, Inc.
-
United States
-
Biotechnology
-
1 - 100 Employee
-
Scientist II
-
Jan 2022 - Aug 2022
-
-
-
Fannin
-
United States
-
Biotechnology Research
-
1 - 100 Employee
-
Therapeutics Intern
-
Sep 2021 - Dec 2021
- Due diligence in lead identification of >1000 compounds after in-silico screening for IP consideration - Identifying strategies to accelerate the therapeutic aspect of the project to reach to the pre-clinical stage. - Due diligence in lead identification of >1000 compounds after in-silico screening for IP consideration - Identifying strategies to accelerate the therapeutic aspect of the project to reach to the pre-clinical stage.
-
-
-
The University of Kansas
-
United States
-
Higher Education
-
700 & Above Employee
-
Postdoctoral researcher/ Cross- functional team lead
-
Dec 2011 - May 2015
- Optimized multiple hits to leads for new biological targets like HCV, Bacterial AraC and dopamine receptors while working with collaborators from KU, NCATS, NIDDK, NIH. - Active time management with literature search, project ideation and publication of >9 projects within 3 years of time frame resulting in 1 patent and 7 publications. - Prepared the scientific presentation slide decks and presented research findings in national and international meetings - Actively mastered the new technologies to accelerate the compound synthesis such as parallel synthesis, flow chemistry, automated chemspeed Show less
-
-
-
Duquesne University
-
United States
-
Higher Education
-
700 & Above Employee
-
Project Initiator and Lead
-
Jul 2009 - Nov 2011
- Conceptulized and led multiple projects to design selective inhibitors of CDK5 as anti-Alzheimer agents to completion resulting in 7 pulications, presentations, awards and a travel grant. - Conducted risk assesment, risk minimization and prioritization of analogs by molecular modelling resulting in a 5-fold selective inhibitor for Alzheimers Disease. - Collaborated internationally and nationally to facilitate project progress and meet deadlines. - Translated knowledge from previous projects to find selective inhibitors of MEK5, a downstream pathway for breast cancer. Show less
-
-
-
Duquesne University
-
United States
-
Higher Education
-
700 & Above Employee
-
Graduate Teaching Assistant
-
Aug 2005 - Jun 2008
I have helped my colleagues teaching assistants in conducting biochemistry laboratory sessions for Pharm. D. students. Also assisted my PhD advisor in literature and patent surveys for grant applications and mentored three graduate students and two undergraduate students in the laboratory. I have helped my colleagues teaching assistants in conducting biochemistry laboratory sessions for Pharm. D. students. Also assisted my PhD advisor in literature and patent surveys for grant applications and mentored three graduate students and two undergraduate students in the laboratory.
-
-
-
Department of Pharmacy SGSITS Indore
-
Indore Area, India
-
Lecturer
-
Jan 2005 - Jul 2005
Taught undergraduate Pharmacy (2nd year) students two full courses on Pharmacognosy and Pathophysiology . Taught undergraduate Pharmacy (2nd year) students two full courses on Pharmacognosy and Pathophysiology .
-
-
Education
-
2005 - 2011
Duquesne University
Ph.D., Medicinal Chemistry -
2002 - 2004
Shri G S Institute of Technology & Science
MS, Medicinal Chemistry -
1998 - 2002
Shri G S Institute of Technology & Science
Bachelors of Pharmacy, Pharmacy
Community
